cytokines or tumor-related proteins) which circulate in the bloodstream, affecting the function of other tissues at a site distant from the tumor origin. The prevalence of HCC-related paraneoplastic erythrocytosis ranges from 1% to 3%. [1, 2] The underlying pathophysiology of HCCrelated paraneoplastic erythrocytosis is multifactorial. Firstly, local hypoxia from focal hepatic tumor necrosis leads to compensatory production of erythropoietin by the kidneys. Secondly, tumor cells themselves can directly produce erythropoietin in response to hypoxia. Thirdly, certain HCC cells are capable of producing "ectopic erythropoietin" even in the absence of tissue hypoxia. [3] Direct evidence of erythropoietin production by HCC cells was demonstrated by electron microscopy and immunohistochemistry of HCC tissue from patients with paraneoplastic erythrocytosis. [4] HCC-related paraneoplastic erythrocytosis is signiÞ cantly associated with large tumor volume, markedly elevated AFP levels, advanced disease and reduced survival. [5] The high erythropoietin levels in such patients are a reß ection of the advanced disease and large tumor burden.
This case illustrates the importance of regular surveillance of hepatitis B carriers as they are 100 times more likely to develop liver cancer compared to uninfected individuals. Furthermore, the development of HCC in these patients may occur in the absence of symptoms or signs.
As the incidence of HCC continues to rise, such paraneoplastic syndromes are likely to be encountered with increasing frequency. It is therefore important to recognize that erythrocytosis may be secondary to underlying HCC. This will aid in a more timely diagnosis of HCC, thus expediting appropriate treatment.
POSSIBLE MECHANISM FOR ZONISAMIDE-INDUCED HYPERAMMONEMIA IN A CHILD WITH CITRULLINEMIA TYPE 1
Sir, Seizures are common symptoms of urea cycle disorders.
[1] Choice of antiepileptic INDIAN JOURNAL OF MEDICAL SCIENCES drugs (AEDs) is limited as many first-line drugs, namely, valproate, carbamazepine, phenobarbitone and topiramate, provoke h y p e r a m m o n e m i a a n d n e u r o l o g i c a l deterioration in these patients. [2] [3] [4] Zonisamide (ZNS), an antiepileptic drug belonging to the sulfonamide group, has demonstrated good efÞ cacy and tolerability in children. A possible ZNS-induced hyperammonemia in a child with citrullinemia is described.
An 8-year-old boy was diagnosed with citrullinemia (Online Mendelian Inheritance in Man 215700) in 2001 at 15 months of age on the basis of acute hyperammonemic encephalopathy and gas chromatography/ mass spectrometry (GC/MS) analysis of urine showing elevated levels of orotic acid and citrulline. Tandem mass spectrometry (MS/ MS) of his blood sample revealed elevated levels of citrulline (555 µM, normal cutoff is 70 µM) and absent arginosuccinate, suggestive of citrullinemia. Since then, he was on an average dietary protein intake of 1 g/kg/day and sodium benzoate (250 mg/kg/day divided in four equal doses). After discontinuation of sodium benzoate from November 2004, his serum ammonia was controlled with dietary protein restriction alone. The serum ammonia in January 2008 was 78 µg/dL (normal, 50-150 µg/dL).
He presented in August 2008 (day 1) with a history of 3 episodes of intermittent blinking of eyes accompanied by blank staring in the last 3 months. There was no history of generalized seizures. The parents reported anorexia (30% to 40% reduction in food intake from the previous recommended level of intake) in the preceding few days. On examination his pulse rate, respiratory rate and BP were 110/ min, 28/min and 110/70 mm /Hg, respectively. His weight, height and head circumference were 20 kg (3 rd -10 th percentile), 118 cm (3 rd -10 th percentile) and 48 cm (<25 th percentile), respectively. He was drowsy and speaking irrelevantly. Systemic examination revealed no abnormality. On day 1, his serum ammonia was 265 µg/dL, blood sugar was 60 mg/dL and blood gas analysis revealed pH-7.45, pCO2-24.3 and bicarbonate-23.5. The serum AST and ALT levels were 31 and 16, respectively. He was treated with IV ß uids (1/3 DNS) (1500 mL over 24 hours) and oral sodium benzoate (250 mg/kg/day divided in three equal doses). Nasogastric tube feeds (2000 calories) were initiated on day 2, along with supplementation of branch-chain amino acids, and protein intake was gradually increased to 1.4 g/kg/day. As intermittent blinking of eyes accompanied by blank staring was suggestive of petitmal seizures, oral ZNS (2 mg/kg/day) was commenced as an off-label use since valproate was contraindicated and ethosuximide is unavailable in India.
On day 3 (48 hours after ZNS was initiated), he developed vomiting, and the serum ammonia was 491 µg/dL. Video EEG performed on day 4 was normal. On day 7, the sensorium deteriorated, with confusion and multiple episodes of vomiting. The serum ammonia level was 495 µg/dL. The persistent hyperammonemia was suspected to be due to ZNS, and the drug was immediately discontinued. The child had a possible adverse drug reaction with ZNS (Naranjo score, 4). [5] Ondansetron (IV, 0.5 mg/kg/day) and oral lansoprazole (30 mg once a day) were commenced, in addition to arginine powder (400 mg/kg/day divided in three equal doses).
The serum ammonia level decreased to 380 µg/ dL on day 9, 267 µg/dL on day 10, 176 µg/dL on day 11 and normalized to 87 µg/dL on day 12. Levels of plasma amino acids performed on day 10 were normal. At discharge the sensorium was normal, vomiting had ceased and appetite had improved, with the child demanding food. He was discharged on sodium benzoate, arginine 200 mg/kg/day and diet with 1.4 g/kg of protein and 2000 calories.
ZNS is structurally and functionally distinct from other AEDs. A wide range of mechanisms of action includes reduction of sustained highfrequency repetitive Þ ring of action potentials by altering the fast inactivation threshold of voltage-dependent sodium channels; and prevention of the spread of seizure discharge by inhibiting low-threshold T-type calcium channels. Additionally, ZNS is a weak inhibitor of carbonic anhydrase. ZNS has been used extensively in children and has been administered to infants as young as 1 month of age. [6] Though it has demonstrated good efÞ cacy and tolerability in children, pediatric use of ZNS is off-label. [6] The only unique adverse effects in children are oligohydrosis and hyperthermia. The package insert does not carry a warning of hyperammonemia or lists urea cycle disorders as a precaution.
[7] The only association with hyperammonemia was described in 4 cases (incidence 1:1, 222,453 exposures). [8] T h e r o l e o f Z N S i n a g g r a v a t i n g hyperammonemia in the present case cannot be dismissed. The fact that it inhibits carbonic anhydrase which in turn reduces availability of bicarbonate ion for carbamyl phosphate synthesis is relevant with the knowledge that some diuretics cause hyperammonemia by inhibition of mitochondrial carbonic anhydrase. [9] This report serves to caution physicians prescribing ZNS and encountering hyperammonemia to suspect ZNS as the likely culprit. As the information available on the package insert does not specify hyperammonemia, the drug may not be withdrawn promptly, if the patient develops signs and symptoms suggestive of hyperammonemia.. Moreover, they should educate patients and the parents to recognize such symptoms early and monitor serum ammonia levels in the appropriate circumstances.
